Merck's Lead-Director Handoff Will Precede Its Current Director's Planned May Retirement

A board member since 2022, the incoming independent lead director formerly chaired and ran Ecolab.

Share
Merck's Lead-Director Handoff Will Precede Its Current Director's Planned May Retirement

Merck, which makes human medicines, vaccines and animal health products, announced Wednesday that Thomas H. Glocer plans to retire from its board in May 2027. Douglas M. Baker, Jr. will take over as independent lead director on January 1, 2027, before Glocer's planned departure.

January Handoff, May Departure

Merck's independent directors selected Baker for the lead-director role, the company said in its Wednesday release. Glocer intends to remain on the board until the annual shareholder meeting in May 2027.

Glocer gave notice Monday of his intention to retire. Merck said his decision did not result from a disagreement about the company's operations, policies or practices.

An Ecolab Veteran Takes Over

Baker has been a director at Merck since 2022. He previously served as Ecolab's chairman and chief executive and is a trustee of Mayo Clinic.

Ecolab provides technologies and services for water and hygiene, serving food, hospitality, industrial and energy markets. Merck pointed to Baker's experience managing organizations and overseeing corporate governance, including public companies' international sales, marketing and operations.

The Business Behind The Board

Merck operates through Pharmaceutical and Animal Health businesses. Its 2025 sales totaled $65.0 billion, according to its annual report, including $58.1 billion from Pharmaceutical and $6.4 billion from Animal Health.

The Pharmaceutical business supplies human medicines and vaccines to customers ranging from hospitals and physicians to wholesalers, retailers, government agencies and managed health care providers. Cancer treatment Keytruda generated $31.7 billion in 2025 sales, including Keytruda Qlex.

Animal Health sells veterinary medicines and vaccines alongside products used to identify and monitor animals. Its customers include veterinarians, distributors, animal producers, farmers and pet owners. Merck uses the MSD name outside the United States and Canada.

Baker's appointment takes effect in January; Glocer's board retirement remains planned for the May shareholder meeting.

Sources

More on Merck

All Merck (MRK) coverage →